Lipoprotein(a)
-
Subject Areas on Research
- Acute reduction of lipoprotein(a) by tissue-type plasminogen activator.
- Acute reduction of lipoprotein(a) by tissue-type plasminogen activator.
- Apheresis to Mitigate Atherosclerotic Vascular Disease.
- Association of Serum Lipoprotein (a) Levels and Coronary Atheroma Volume by Intravascular Ultrasound.
- Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography.
- Concentration of Lp(a) (Lipoprotein[a]) in Aneurysm Sac Is Associated With Wall Enhancement of Unruptured Intracranial Aneurysm.
- Cord blood lipids in infants born to HIV-1-infected women treated with combination antiretroviral therapy.
- Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries.
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
- Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.
- Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site.
- Genetic associations with valvular calcification and aortic stenosis.
- Isolation and characterization of the two major apoproteins in human lipoprotein [a].
- JCL Roundtable: Global Think Tank on Lipoprotein(a).
- JCL roundtable-Lipoprotein(a): The emerging risk factor.
- Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation.
- Kinetic analysis of the effects of heparin and lipoproteins on tissue plasminogen activator mediated plasminogen activation.
- Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort.
- Lipoprotein (a) in the regulation of fibrinolysis.
- Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.
- Lipoprotein (a) regulates plasmin generation and inhibition.
- Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations.
- Lipoprotein (a): purification and kinetic analysis.
- Lipoprotein a inhibits streptokinase-mediated activation of human plasminogen.
- Lipoprotein(A) and effective renal plasma flow rate in older patients with arteriosclerotic diseases.
- Lipoprotein(a) Testing Patterns in a Large Health System.
- Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
- Lipoprotein(a) and apolipoproteins B and A-I after acute myocardial infarction.
- Lipoprotein(a) and its role in atherothrombotic disease.
- Lipoprotein(a) and silent myocardial ischemia in IDDM.
- Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.
- Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator.
- Lipoprotein(a) inhibits plasminogen activation in a template-dependent manner.
- Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension.
- Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
- Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
- Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation.
- Relation of High Lipoprotein (a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease.
- Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B.
- Results of Expert Meetings: Obesity and Cardiovascular Disease. Obesity as a risk factor in coronary artery disease.
- The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes : the atherosclerosis risk in communities study.
- The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein(a).
- Why is lipoprotein(a) relevant to thrombosis?
-
Keywords of People
- Schanberg, Laura Eve, Professor of Pediatrics, Pediatrics, Rheumatology